Presentation is loading. Please wait.

Presentation is loading. Please wait.

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers  Morana Vojnic, MD, Daisuke Kubota, MD, PhD, Christopher.

Published byHendri Lesmana Modified over 5 years ago

Similar presentations

Presentation on theme: "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers  Morana Vojnic, MD, Daisuke Kubota, MD, PhD, Christopher."— Presentation transcript:

1 Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers  Morana Vojnic, MD, Daisuke Kubota, MD, PhD, Christopher Kurzatkowski, BSc, Michael Offin, MD, Ken Suzawa, MD, PhD, Ryma Benayed, PhD, Adam J. Schoenfeld, MD, Andrew J. Plodkowski, MD, John T. Poirier, PhD, Charles M. Rudin, MD, PhD, Mark G. Kris, MD, Neal X. Rosen, MD, Helena A. Yu, MD, Gregory J. Riely, MD, PhD, Maria E. Arcila, MD, Romel Somwar, PhD, Marc Ladanyi, MD  Journal of Thoracic Oncology  Volume 14, Issue 5, Pages (May 2019) DOI: /j.jtho Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Clinical information for patients with resistance to EGFR tyrosine kinase inhibitor and BRAF fusions. (A) Disease course of patient 2, who was found to have acquired resistance to osimertinib and acylglycerol kinase gene (AGK)/BRAF fusion. (B) Disease course of patient 4, who was found to have acquired resistance to erlotinib and progressive mediastinal disease with AGK/BRAF fusion. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Generation and characterization of CRISPR/Cas9 acylglycerol kinase gene (AGK)/BRAF cell lines. (A) clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 genome engineering protocol scheme. (B) Expression of AGK/BRAF. (C). Sanger sequencing of polymerase chain reaction (PCR) product confirming fusion in cell line of AGK exon 2 with exon 8 of BRAF. (D) H1975 and PC9 cells expressing AGK/BRAF were treated with 0.5 osimertinib for 1 hour, whole-cell extracts were prepared, and then lysates were subjected to immunoblotting. The results represent three independent experiments. (E) The indicated cell lines were plated at a density 7500/well in 96-well plates and treated with osimertinib for 96 hours; the concentration that inhibits 50% (IC50) values for growth inhibition are shown in the Table (F). (G and H) Cells were plated at a density of 150,000 cells/well in six-well plates and then infected 24 hours later with lentiviruses harboring the indicated short hairpin RNAs (shRNAs) and then selected with puromycin 48 hours later. BRAF mRNA levels was determined by quantitative reverse-transcriptase PCR (G) or cells were replated in osimertinib and growth assessed 96 hours later (H). The IC50 values for growth inhibition were determined by nonlinear regression analysis by using Graphpad Prism software (GraphPad Software). The results represent the mean plus or minus SD of two experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; gDNA, guide DNA; p, phosphorylated; STAT3, signal transducer and activator of transcription 3; PJA2, praja ring finger ubiquitin ligase 2; -RT, control reaction without reverse transcriptase. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 2 Generation and characterization of CRISPR/Cas9 acylglycerol kinase gene (AGK)/BRAF cell lines. (A) clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 genome engineering protocol scheme. (B) Expression of AGK/BRAF. (C). Sanger sequencing of polymerase chain reaction (PCR) product confirming fusion in cell line of AGK exon 2 with exon 8 of BRAF. (D) H1975 and PC9 cells expressing AGK/BRAF were treated with 0.5 osimertinib for 1 hour, whole-cell extracts were prepared, and then lysates were subjected to immunoblotting. The results represent three independent experiments. (E) The indicated cell lines were plated at a density 7500/well in 96-well plates and treated with osimertinib for 96 hours; the concentration that inhibits 50% (IC50) values for growth inhibition are shown in the Table (F). (G and H) Cells were plated at a density of 150,000 cells/well in six-well plates and then infected 24 hours later with lentiviruses harboring the indicated short hairpin RNAs (shRNAs) and then selected with puromycin 48 hours later. BRAF mRNA levels was determined by quantitative reverse-transcriptase PCR (G) or cells were replated in osimertinib and growth assessed 96 hours later (H). The IC50 values for growth inhibition were determined by nonlinear regression analysis by using Graphpad Prism software (GraphPad Software). The results represent the mean plus or minus SD of two experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; gDNA, guide DNA; p, phosphorylated; STAT3, signal transducer and activator of transcription 3; PJA2, praja ring finger ubiquitin ligase 2; -RT, control reaction without reverse transcriptase. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 2 Generation and characterization of CRISPR/Cas9 acylglycerol kinase gene (AGK)/BRAF cell lines. (A) clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 genome engineering protocol scheme. (B) Expression of AGK/BRAF. (C). Sanger sequencing of polymerase chain reaction (PCR) product confirming fusion in cell line of AGK exon 2 with exon 8 of BRAF. (D) H1975 and PC9 cells expressing AGK/BRAF were treated with 0.5 osimertinib for 1 hour, whole-cell extracts were prepared, and then lysates were subjected to immunoblotting. The results represent three independent experiments. (E) The indicated cell lines were plated at a density 7500/well in 96-well plates and treated with osimertinib for 96 hours; the concentration that inhibits 50% (IC50) values for growth inhibition are shown in the Table (F). (G and H) Cells were plated at a density of 150,000 cells/well in six-well plates and then infected 24 hours later with lentiviruses harboring the indicated short hairpin RNAs (shRNAs) and then selected with puromycin 48 hours later. BRAF mRNA levels was determined by quantitative reverse-transcriptase PCR (G) or cells were replated in osimertinib and growth assessed 96 hours later (H). The IC50 values for growth inhibition were determined by nonlinear regression analysis by using Graphpad Prism software (GraphPad Software). The results represent the mean plus or minus SD of two experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; gDNA, guide DNA; p, phosphorylated; STAT3, signal transducer and activator of transcription 3; PJA2, praja ring finger ubiquitin ligase 2; -RT, control reaction without reverse transcriptase. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

6 Figure 3 Characterization of an EGFR-mutant cell line with praja ring finger ubiquitin ligase 2 gene (PJA2)/BRAF fusion. (A) Expression of PJA2/BRAF in a patient-derived cell line, MSK-LX138cl, and xenograft tissue. (B) Sanger sequencing of the polymerase chain reaction product, confirming a fusion between PJA2 exon 7 and BRAF exon 11. (C) MSK-LX138cl cells were treated with 0.5 μM osimertinib for 1 hour, whole-cell extracts were prepared, and then lysates were subjected to immunoblotting. The results represent 3 independent experiments. (D–E) MSK-LX138cl cells were plated at a density 7500/well in 96-well plates and treated with EGFR (D) or BRAF (E) inhibitors. The concentration that inhibits 50% (IC50) values for growth inhibition were determined by nonlinear regression analysis using Graphpad Prism software (GraphPad Software). (F) A quantity of 50,000 MSK-LX138cl cells/well were plated in 96-well plates, and the next day they were treated with 0.1 or 1 μM of the indicated agents or a combination of osimertinib and trametinib. Caspase 3/7 activity was determined 48 hours later. The results represent the mean plus or minus SD of two experiments. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; cDNA, complementary DNA. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

7 Figure 4 Combined inhibition of MEK and EGFR is effective in reducing growth of cells with EGFR mutation. (A) Cells were plated at a density of 7500 cells/well in 96-well plate and treated with vemurafenib or dabrafenib for 96 hours, after which growth was determined. The concentration that inhibits 50% (IC50) values for growth inhibition are shown (right). (B) MSK-LX138cl cells were plated at a density of 7500 cells/well in 96-well plates and treated with trametinib (0–1 μM) and osimertinib (0–1μM) for 96 hours. Growth inhibition was then determined and the combination index was calculated by using CompuSyn software. Data represent the mean value of growth inhibition ratio at each concentration of the drugs in two independent experiments. Dot plot indicates the combination index and fraction affected (inhibition ratio) of various drug concentrations. AGK, acylglycerol kinase. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

8 Figure 5 The pan-RAF inhibitor LY effectively inhibits growth of EGFR-mutant cell lines with BRAF fusions. (A) Cells were plated in 96-well plates and treated with LY , after which growth was determined (left). The concentration that inhibits 50% (IC50) values for growth inhibition were determined by nonlinear regression analysis by using GraphPad Prism software (GraphPad Software) (right). (B) MSK-LX138cl cells were treated with the indicated concentration of LY or vemurafenib for 1 hour, and then whole-cell extracts were prepared and immunoblotted for the indicated proteins. The results are representative of two independent experiments. (C) Cells were treated with 0.1 or 1 μM of the indicated compounds or osimertinib/trametinib combinations, and caspase 3/7 activity was determined 48 hours later. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2019 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers  Morana Vojnic, MD, Daisuke Kubota, MD, PhD, Christopher."

Similar presentations

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
From: Glucose Infusion Suppresses Surgery-induced Muscle Protein Breakdown by Inhibiting Ubiquitin-proteasome Pathway in Rats Anesthes. 2009;110(1):81-88.

From: Glucose Infusion Suppresses Surgery-induced Muscle Protein Breakdown by Inhibiting Ubiquitin-proteasome Pathway in Rats Anesthes. 2009;110(1):81-88.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib  Yiyu Zou, PhD, Yi-He.
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.
Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2  David Mauchley, MD, Xianzhong Meng, MD, PhD, Thomas.

Modulation of growth in human esophageal adenocarcinoma cells by group IIa secretory phospholipase A2  David Mauchley, MD, Xianzhong Meng, MD, PhD, Thomas.
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.
Differential expression of Hedgehog/Notch and transforming growth factor-β in human abdominal aortic aneurysms  Adam J. Doyle, MD, Eileen M. Redmond,

Differential expression of Hedgehog/Notch and transforming growth factor-β in human abdominal aortic aneurysms  Adam J. Doyle, MD, Eileen M. Redmond,
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo  Jessica A. Yu, MD, David Mauchley, MD, Howard Li, MD, Xianzhong.

Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo  Jessica A. Yu, MD, David Mauchley, MD, Howard Li, MD, Xianzhong.
Rafal Dziadziuszko, MD, PhD, Anh T

Rafal Dziadziuszko, MD, PhD, Anh T
T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis  Hugo Gortais,
Mechanisms of p53 Restriction in Merkel Cell Carcinoma Cells Are Independent of the Merkel Cell Polyoma Virus T Antigens  Roland Houben, Christina Dreher,

Mechanisms of p53 Restriction in Merkel Cell Carcinoma Cells Are Independent of the Merkel Cell Polyoma Virus T Antigens  Roland Houben, Christina Dreher,
Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.
Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma  Nicolas Guibert,
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Inna V. Fedorenko, Jennifer A. Wargo, Keith T. Flaherty, Jane L

Inna V. Fedorenko, Jennifer A. Wargo, Keith T. Flaherty, Jane L
VAMP2–NRG1 Fusion Gene is a Novel Oncogenic Driver of Non–Small-Cell Lung Adenocarcinoma  Yeonjoo Jung, PhD, Seunghui Yong, BS, Pora Kim, PhD, Hee-Young.

VAMP2–NRG1 Fusion Gene is a Novel Oncogenic Driver of Non–Small-Cell Lung Adenocarcinoma  Yeonjoo Jung, PhD, Seunghui Yong, BS, Pora Kim, PhD, Hee-Young.

Similar presentations

Ads by Google